Plain-language summary
A focused review that gathers the human and animal evidence for carnosine in cardiometabolic disease — insulin resistance, dyslipidaemia, hypertension, and the cluster syndrome that links them. The authors argue that the molecule's dual antioxidant and carbonyl-quenching chemistry is precisely the intervention this disease cluster needs.
Key takeaways
- ›Frames metabolic syndrome as a carnosine-deficiency phenotype.
- ›Reviews mechanistic and clinical evidence in one place.
- ›Influential anchor for follow-on trials in metabolic health.
About this summary
The summary and key takeaways above are written by our editorial team in plain language for general readers. They are not the original abstract. For the authors' own wording, methodology, statistics, and full reference list, follow the source link to the published record.